ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Taking PMN Private

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Dec 01, 2021 3:53pm

76 Views

Post# 34186881

RE:RE:Taking PMN Private

G19, It seems we are in the same place we were last year hovering around the low teens.
If history proves itself, we might see the SP increase. Keep in mind, if we get back to back PR's we may a see a few basis points up.

My Personal Exit Points since I don't see PMN doing anything major in 2022

Pre-consolidation - Exit at 0.20
Post-consolidation - Exit at $10.00

Both Exits are pretty much my Break Evens.

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week